Literature DB >> 3755661

Evaluation of a Bayesian regression-analysis computer program for predicting phenytoin concentration.

T M Ludden, S L Beal, C C Peck, P J Godley.   

Abstract

A microcomputer program using Bayesian regression analysis to predict serum phenytoin concentrations was evaluated. Phenytoin concentration-time data from nine healthy male volunteers and one male patient were obtained from published studies. For two different dosage regimens that each subject received, the last available predose concentration on the sixth day of the regimen was predicted using observed predose concentrations on both the morning of the third day and on each of the first three days of phenytoin administration. In nine subjects who received at least 10 days of phenytoin therapy, observed concentrations after more than 10 days of therapy were predicted using both one and three observed serum concentrations. Also, in six subjects, the observed predose concentrations for the first three days of an initial phenytoin regimen were used to predict the last predose concentration observed during each subject's second regimen. Predictive performance of the program was evaluated using mean error (m.e.) as a measure of bias, mean absolute error (m.a.e.) as a measure of precision, and root mean square error (r.m.s.e.) as a composite measure of bias and precision. The majority of the predicted serum concentrations were accurate. Predictions of serum concentrations after six days and after more than 10 days of phenytoin therapy were somewhat more accurate when three serum concentrations were used than when only one concentration was used. In the six subjects for whom concentrations from an initial regimen were used to predict those in a second regimen, the largest prediction error was 5 mg/L (m.e. 0.88, m.a.e. 1.9, and r.m.s.e. 2.4).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3755661

Source DB:  PubMed          Journal:  Clin Pharm        ISSN: 0278-2677


  9 in total

Review 1.  Therapeutic drug monitoring of phenytoin. Rationale and current status.

Authors:  M Levine; T Chang
Journal:  Clin Pharmacokinet       Date:  1990-11       Impact factor: 6.447

Review 2.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

3.  Evaluation of a bayesian pharmacokinetic program for phenytoin concentration predictions in outpatient population.

Authors:  J M Gaulier; R Boulieu; C Fischer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1998 Apr-Jun       Impact factor: 2.441

Review 4.  Clinical pharmacokinetics 1990.

Authors:  G R Matzke; W L St Peter
Journal:  Clin Pharmacokinet       Date:  1990-01       Impact factor: 6.447

5.  Evaluation of a proposed method for phenytoin maintenance dose prediction following an intravenous loading dose.

Authors:  J J Crowley; J R Koup; B J Cusack; T M Ludden; R E Vestal
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

6.  Phenytoin dosage predictions in paediatric patients.

Authors:  G J Yuen; P T Latimer; L C Littlefield; R W Mackey
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

Review 7.  An updated comparison of drug dosing methods. Part I: Phenytoin.

Authors:  R D Pryka; K A Rodvold; S M Erdman
Journal:  Clin Pharmacokinet       Date:  1991-03       Impact factor: 6.447

Review 8.  Pharmacokinetic optimisation of anticonvulsant therapy.

Authors:  A H Thomson; M J Brodie
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

9.  Practical computer-assisted dosing for aminoglycoside antibiotics.

Authors:  L A Lenert; H Klostermann; R W Coleman; J Lurie; T F Blaschke
Journal:  Antimicrob Agents Chemother       Date:  1992-06       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.